AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...
Business Insider18h
AstraZeneca: Overcoming Short-term Challenges with Robust Long-term Potential
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...
It News Online7h
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion ...
Reporters tweets about ‘vague whispers’ of bid interest in TG Therapeutics
Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: ...
AirBnB and 5 More High-Quality Stocks for a Market Rally
All 11 sectors are in the green for the year. The optimism comes as the economy is likely to continue to grow because the ...
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...
Indiatimes19h
AstraZeneca Pharma India Share Price
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,267.00 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...